Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Procrit Critical Care Label Expansion Could Fuel Franchise Sales, J&J Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Johnson & Johnson remains committed to the anemia agent despite failing to return the franchise to growth in 2005.

You may also be interested in...

J&J Files Antitrust Complaint Against Amgen For Aranesp Pricing Practice

Amgen's bundling of rebates for Aranesp, Neulasta and Neupogen have unfairly increased the anemia therapy's market share, the complaint alleges.

Procrit Could Return To Growth Later This Year, J&J Says

Anemia therapy should reverse a quarterly sales decline brought on by competition from Amgen, Johnson & Johnson maintains. Worldwide sales were up for the second quarter.

J&J Draws Line On Procrit Pricing; Will Not Match Amgen Aranesp 40% Discounts

Procrit sales are the one weak spot in a strong quarter overall. J&J is moving away from its previous policy of retaining a "level playing field" between Procrit and Aranesp pricing; the strategy now is to have a "reasonably level playing field."





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts